Prognostic Biomarker Testing in CLL/SLL Remains Low
Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.
Diagnosis & Disease Information
TOURMALINE-MM2: Ixazomib Plus Lenalidomide and Dexamethasone for Newly Diagnosed MM
A phase 3 trial showed a trend toward improved PFS with ixazomib plus lenalidomide and dexamethasone.
Prognostic Biomarker Testing in CLL/SLL Remains Low
Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.
Liso-Cel Plus Ibrutinib Demonstrated Efficacy in R/R CLL/SLL
A phase 1 trial demonstrated antitumor activity of liso-cel plus ibrutinib with low rates of grade 3 or higher CRS and neurotoxicity among heavily pretreated patients with CLL/SLL.
Umbralisib Plus Ublituximab Improved PFS vs Chemoimmunotherapy in CLL
The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.
Promising Efficacy Seen With LOXO-305 in R/R CLL/SLL
LOXO-305 treatment of heavily pretreated CLL/SLL resulted in durable, high response rates in a phase 1/2 trial.
Older Patients With NHL Are at Higher Risk for Hospitalization vs Non-Cancer Controls
The average spending per hospitalization during the course of 5 years was higher for survivors of NHL compared with controls ($16,950 vs. $13,474).
Sociodemographic Characteristics a Strong Factor in EOL Healthcare Utilization in Acute Myeloid Leukemia
Researchers sought to determine how and which factors contribute to healthcare utilization by patients with AML at the end of life.
Cytarabine in Young Adults With AML: Subcutaneous Injection Noninferior to IV Infusion
Open-label, randomized clinical trial sought to determine noninferiority of subcutaneous and IV infusion cytarabine in young adults with AML.
Survival Improving for Patients With Acute Lymphoblastic Leukemia Who Experience Relapse Following HSCT
Researchers identify factors that influence relapse after HSCT in patients with acute lymphoblastic leukemia.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...